1. Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre randomized, vehicle‐controlled clinical study. (1st February 2018) Authors: Nakagawa, H.; Nemoto, O.; Igarashi, A.; Nagata, T. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: e169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre randomized, vehicle‐controlled clinical study. (14th February 2018) Authors: Nakagawa, H.; Nemoto, O.; Igarashi, A.; Nagata, T. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: e169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre, randomized, vehicle‐controlled clinical study. (1st February 2018) Authors: Nakagawa, H.; Nemoto, O.; Igarashi, A.; Nagata, T. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: 424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre, randomized, vehicle‐controlled clinical study. (15th January 2018) Authors: Nakagawa, H.; Nemoto, O.; Igarashi, A.; Nagata, T. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: 424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and efficacy of guselkumab in Japanese patients with moderate‐to‐severe plaque psoriasis: a randomized, placebo‐controlled, ascending‐dose study. (17th January 2018) Authors: Nemoto, O.; Hirose, K.; Shibata, S.; Li, K.; Kubo, H. Journal: British journal of dermatology Issue: Volume 178:Number 3(2018) Page Start: 689 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and efficacy of guselkumab in Japanese patients with moderate‐to‐severe plaque psoriasis: a randomized, placebo‐controlled, ascending‐dose study. (1st March 2018) Authors: Nemoto, O.; Hirose, K.; Shibata, S.; Li, K.; Kubo, H. Journal: British journal of dermatology Issue: Volume 178:Number 3(2018) Page Start: 689 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab improves the signs and symptoms of moderate‐to‐severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double‐blind, placebo‐controlled, phase 2 dose‐ranging study. (13th December 2013) Authors: Sigurgeirsson, B.; Kircik, L.; Nemoto, O.; Mikazans, I.; Haemmerle, S.; Thurston, H.J.; Papavassilis, C.; Richards, H.B. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 28:Number 8(2014:Aug.) Page Start: 1127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study. (1st February 2016) Authors: Nemoto, O.; Furue, M.; Nakagawa, H.; Shiramoto, M.; Hanada, R.; Matsuki, S.; Imayama, S.; Kato, M.; Hasebe, I.; Taira, K.; Yamamoto, M.; Mihara, R.; Kabashima, K.; Ruzicka, T.; Hanifin, J.; Kumagai, Y. Journal: British journal of dermatology Issue: Volume 174:Number 2(2016) Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study3. (19th December 2015) Authors: Nemoto, O.; Furue, M.; Nakagawa, H.; Shiramoto, M.; Hanada, R.; Matsuki, S.; Imayama, S.; Kato, M.; Hasebe, I.; Taira, K.; Yamamoto, M.; Mihara, R.; Kabashima, K.; Ruzicka, T.; Hanifin, J.; Kumagai, Y. Journal: British journal of dermatology Issue: Volume 174:Number 2(2016) Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 局部JTE‐052(一种Janus激酶抑制剂) 对患有中度至重度异位性皮炎的日本成人患者的功效和安全性:一项2期、多中心随机、赋形剂对照临床研究. (14th February 2018) Authors: Nakagawa, H.; Nemoto, O.; Igarashi, A.; Nagata, T. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: e186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗